Michael Silverman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael Silverman has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Elisabeth Kuehni
Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
2 shared publications Adrian M Brooke
The Leicester Children's Asthma Centre, Division of Child Health, Department of Infection, Immunity & Inflammation, University of Leicester, Leicester, LE2 7LX, UK
1 shared publicationAlbert L. Sheffer
Department of Medicine, Harvard Medical School, Boston, MA, USA
1 shared publicationAlbert Sheffer
1 shared publicationAnthony Davis
Specialist Community Child Health Services, Leicester City PCT, Bridge Park Plaza, Thurmaston, Leicester, LE4 8PQ, UK
1 shared publication- Ben Daniel Spycher
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
1 shared publication
Latest Publications
- Open Access
- 17 January 2013
- Published by Springer Nature
Trial of self-management for young children with asthma
- 17 January 2013
- Published by Springer Nature
Open AccessTrial of self-management for young children with asthma
- Open Access
- 1 October 2007
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 36 (5) , 977-985
Cohort Profile: The Leicester Respiratory Cohorts
Asthma and other wheezing disorders are the most common chronic health problems in childhood and place a large burden on children, their families and society.1 Prevalence is highest in infancy or early childhood and the aetiology is complex, with a strong influence of intrauterine and early life exposures. Clinical presentation, response to treatment and prognosis differ by age and the natural history is highly variable. It has been questioned whether asthma, especially in young children, should be regarded as one disease with a single underlying aetiology but a wide range of severity,2 or as a syndrome comprising several separate conditions.3, 4 Furthermore, respiratory illness in early life is associated with adult respiratory disease and diminished lung function.5, 6 Despite this, most epidemiological studies of asthma before the 1990s had focused on schoolchildren and adults, and there were sparse population-based data on infants and preschool children.
- 1 October 2007
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 36 (5) , 977-985
Open AccessCohort Profile: The Leicester Respiratory Cohorts
Asthma and other wheezing disorders are the most common chronic health problems in childhood and place a large burden on children, their families and society.1 Prevalence is highest in infancy or early childhood and the aetiology is complex, with a strong influence of intrauterine and early life exposures. Clinical presentation, response to treatment and prognosis differ by age and the natural history is highly variable. It has been questioned whether asthma, especially in young children, should be regarded as one disease with a single underlying aetiology but a wide range of severity,2 or as a syndrome comprising several separate conditions.3, 4 Furthermore, respiratory illness in early life is associated with adult respiratory disease and diminished lung function.5, 6 Despite this, most epidemiological studies of asthma before the 1990s had focused on schoolchildren and adults, and there were sparse population-based data on infants and preschool children.
- 1 September 2007
- Published by Elsevier in The Lancet
- Vol. 370 (9589) , 717-719
Early lung development and COPD
- 1 September 2007
- Published by Elsevier in The Lancet
- Vol. 370 (9589) , 717-719
Early lung development and COPD
- 28 March 2006
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 17 (s17) , 14-20
Safety and tolerability of inhaled budesonide in children in the Steroid Treatment As Regular Therapy in early asthma (START) trial
The safety and tolerability of asthma medications are still a concern to many asthma patients receiving long-term treatment. Therefore, more safety data from long-term, controlled trials are needed. The aim of this study was to evaluate the safety and tolerability of long-term treatment with once-daily budesonide in children aged 5-10 yrs with mild persistent asthma of recent onset in the inhaled Steroid Treatment As Regular Therapy in early asthma (START) study. Children aged 5-10 yrs with early asthma were randomized to double-blind treatment with budesonide 200 microg or placebo once daily via Turbuhaler in addition to usual asthma therapy, for 3 yrs. Adverse events were recorded from both spontaneous reports and responses to standard questions, and asthma-related events and asthma control were recorded between visits and subsequently graded by the blinded investigators. Of the study population of 1981 children (1004 budesonide and 977 usual care), 81% (812 of 1004) in the budesonide group and 82% (797 of 977) in the usual care group experienced a total of 6414 events listed by preferred term (3209 budesonide plus usual care and 3205 placebo plus usual care). The most commonly reported events included respiratory infection, pharyngitis, rhinitis, viral infection and bronchitis, and there were no clinically relevant differences in incidence between treatments. There were no reports of tuberculosis or aspergillosis, and no evidence of increased risk of systemic or ocular adverse events with budesonide relative to placebo. There were 106 serious adverse events in the budesonide group and 128 with usual care. The most frequent, aggravated asthma, was more common with usual care than with budesonide. There were no deaths among children participating in START. In conclusion, the addition of once-daily inhaled budesonide 200 microg via Turbuhaler to usual care is safe and well tolerated in children with recent-onset mild persistent asthma.
- 28 March 2006
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 17 (s17) , 14-20
Safety and tolerability of inhaled budesonide in children in the Steroid Treatment As Regular Therapy in early asthma (START) trial
The safety and tolerability of asthma medications are still a concern to many asthma patients receiving long-term treatment. Therefore, more safety data from long-term, controlled trials are needed. The aim of this study was to evaluate the safety and tolerability of long-term treatment with once-daily budesonide in children aged 5-10 yrs with mild persistent asthma of recent onset in the inhaled Steroid Treatment As Regular Therapy in early asthma (START) study. Children aged 5-10 yrs with early asthma were randomized to double-blind treatment with budesonide 200 microg or placebo once daily via Turbuhaler in addition to usual asthma therapy, for 3 yrs. Adverse events were recorded from both spontaneous reports and responses to standard questions, and asthma-related events and asthma control were recorded between visits and subsequently graded by the blinded investigators. Of the study population of 1981 children (1004 budesonide and 977 usual care), 81% (812 of 1004) in the budesonide group and 82% (797 of 977) in the usual care group experienced a total of 6414 events listed by preferred term (3209 budesonide plus usual care and 3205 placebo plus usual care). The most commonly reported events included respiratory infection, pharyngitis, rhinitis, viral infection and bronchitis, and there were no clinically relevant differences in incidence between treatments. There were no reports of tuberculosis or aspergillosis, and no evidence of increased risk of systemic or ocular adverse events with budesonide relative to placebo. There were 106 serious adverse events in the budesonide group and 128 with usual care. The most frequent, aggravated asthma, was more common with usual care than with budesonide. There were no deaths among children participating in START. In conclusion, the addition of once-daily inhaled budesonide 200 microg via Turbuhaler to usual care is safe and well tolerated in children with recent-onset mild persistent asthma.
- 1 December 2005
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 95 (6) , 566-570
Outcome of pregnancy in a randomized controlled study of patients with asthma exposed to budesonide
- 1 December 2005
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 95 (6) , 566-570
Outcome of pregnancy in a randomized controlled study of patients with asthma exposed to budesonide
- Open Access
- 1 June 2004
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 23 (6) , 795-796
Inhaled corticosteroids and the growth of lung function in children
First, the design of the two studies is quite different. Devulapalli et al. 1 carried out a longitudinal observational study of a population sample in which young children who were prescribed ICS for “recurrent bronchial obstruction” (undefined) were compared with untreated symptomatic and symptom-free groups. Although the design is justified as being “based upon … real life”, it suffers from the shortfall that an independent effect of ICS on functional outcome cannot be deduced from the results presented. At best, it is possible to conclude that both treated and untreated young children with recurrent bronchial obstruction appear functionally to return towards normal by 2 yrs of age. Multivariate analysis might have added strength to the assumption that this process was indeed related in someway to ICS therapy, rather than being simply a reflection of the natural history of the disorder.
- 1 June 2004
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 23 (6) , 795-796
Open AccessInhaled corticosteroids and the growth of lung function in children
First, the design of the two studies is quite different. Devulapalli et al. 1 carried out a longitudinal observational study of a population sample in which young children who were prescribed ICS for “recurrent bronchial obstruction” (undefined) were compared with untreated symptomatic and symptom-free groups. Although the design is justified as being “based upon … real life”, it suffers from the shortfall that an independent effect of ICS on functional outcome cannot be deduced from the results presented. At best, it is possible to conclude that both treated and untreated young children with recurrent bronchial obstruction appear functionally to return towards normal by 2 yrs of age. Multivariate analysis might have added strength to the assumption that this process was indeed related in someway to ICS therapy, rather than being simply a reflection of the natural history of the disorder.
- 1 August 2003
- Published by BMJ in Archives of Disease in Childhood
- Vol. 88 (8) , 743
Lung function and low birth weight
- 1 August 2003
- Published by BMJ in Archives of Disease in Childhood
- Vol. 88 (8) , 743
Lung function and low birth weight
- Open Access
Episodic viral wheeze in preschool children: effect of topical nasal corticosteroid prophylaxis
Background: The effect of prophylactic nasal corticosteroids on wheezing episodes associated with colds was investigated in a 12 week parallel group, double blind, randomised controlled trial in preschool children. Methods: Data were collected from 50 children aged 12–54 months with a history of at least three episodes of wheeze associated with colds over the previous winter, but few or no interval symptoms; 24 were given one dose of fluticasone aqueous nasal spray (50 μg) into each nostril twice daily and 26 received an indistinguishable placebo spray. Episodes of lower respiratory illness occurring within 2 days of the onset of a cold were identified from daily symptom diaries. The main outcome was nocturnal symptom score during the first 7 days of an episode. Results: The groups were well balanced on entry except that the treatment group had a history of more prolonged episodes. During the trial there was no significant difference in the number of episodes in the treatment and control groups (27 and 37, respectively), in the severity of nocturnal symptoms (mean score 1.33 and 1.22, respectively, confidence interval of difference −0.24 to +0.47) or in daytime symptoms, activity or total scores during episodes. Compliance was estimated to be over 50% in 43 of the children. Conclusions: Nasal corticosteroid treatment does not prevent acute wheezy episodes associated with upper respiratory infections (common colds) in preschool children.
Open AccessEpisodic viral wheeze in preschool children: effect of topical nasal corticosteroid prophylaxis
Background: The effect of prophylactic nasal corticosteroids on wheezing episodes associated with colds was investigated in a 12 week parallel group, double blind, randomised controlled trial in preschool children. Methods: Data were collected from 50 children aged 12–54 months with a history of at least three episodes of wheeze associated with colds over the previous winter, but few or no interval symptoms; 24 were given one dose of fluticasone aqueous nasal spray (50 μg) into each nostril twice daily and 26 received an indistinguishable placebo spray. Episodes of lower respiratory illness occurring within 2 days of the onset of a cold were identified from daily symptom diaries. The main outcome was nocturnal symptom score during the first 7 days of an episode. Results: The groups were well balanced on entry except that the treatment group had a history of more prolonged episodes. During the trial there was no significant difference in the number of episodes in the treatment and control groups (27 and 37, respectively), in the severity of nocturnal symptoms (mean score 1.33 and 1.22, respectively, confidence interval of difference −0.24 to +0.47) or in daytime symptoms, activity or total scores during episodes. Compliance was estimated to be over 50% in 43 of the children. Conclusions: Nasal corticosteroid treatment does not prevent acute wheezy episodes associated with upper respiratory infections (common colds) in preschool children.
- 1 August 2000
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 162 (Supplement) , S1
Introduction
- 1 August 2000
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 162 (Supplement) , S1
Introduction